We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CIT:GETTEXCintas Corporation Analysis

Data as of 2026-06-20 - not real-time

$143.06

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Citigroup is trading at $143.06, comfortably above its 20‑day (≈133.07), 50‑day (≈129.58) and 200‑day (≈113.31) moving averages, confirming a strong bullish trend. Technical momentum is reinforced by a bullish MACD (line ≈ 4.52 above signal ≈ 3.36) and an increasing volume trend, though the RSI is elevated at 71.6, suggesting the stock is nearing overbought territory and may face short‑term resistance near $147.96. The equity exhibits a beta of roughly 1.37 and 30‑day volatility of 27 %, indicating higher market sensitivity and price swings.
Fundamentally, the forward P/E of 11.4 is well below the industry average of 16.9, and the consensus target price of $147.07 offers modest upside (~2.8%). Revenue is growing at 16 % YoY, while the dividend yield of 1.68 % with a payout ratio under 30 % appears sustainable given the company’s net cash position (cash ≈ $1.05 trillion vs debt ≈ $0.82 trillion). However, operating cash flow is negative and ROE is modest (~7 %). Overall, the stock balances growth prospects with value metrics, making it a reasonable buy for investors comfortable with its volatility and regulatory exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and price above key moving averages
  • RSI in overbought zone, suggesting potential pull‑back
  • Proximity to resistance at $147.96

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward P/E of 11.4 vs industry 16.9 indicating valuation upside
  • Consensus target price implying ~2.8% upside
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong net cash position offsetting debt load
  • Revenue growth of ~16% and diversified global footprint
  • Blend of growth and value characteristics with modest dividend yield

Key Metrics & Analysis

Financial Health

Revenue Growth15.90%
Profit Margin20.36%
P/E Ratio17.7
ROE7.65%
ROA0.61%
P/B Ratio1.3
Op. Cash Flow$-30797000704
Industry P/E16.9

Technical Analysis

TrendBullish
RSI71.6
Support$123.24
Resistance$147.96
MA 20$133.07
MA 50$129.58
MA 200$113.31
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46

Valuation

Target Price$147.07
Upside/Downside2.80%
GradeFair
TypeBlend
Dividend Yield1.68%

Risk Assessment

Beta1.37
Volatility27.02%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.